Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.

@article{LpezMuoz2009MonoaminergicNT,
  title={Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.},
  author={F. L{\'o}pez-Mu{\~n}oz and C. {\'A}lamo},
  journal={Current pharmaceutical design},
  year={2009},
  volume={15 14},
  pages={
          1563-86
        }
}
  • F. López-Muñoz, C. Álamo
  • Published 2009
  • Medicine
  • Current pharmaceutical design
  • The 1950s saw the clinical introduction of the first two specifically antidepressant drugs: iproniazid, a monoamine-oxidase inhibitor that had been used in the treatment of tuberculosis, and imipramine, the first drug in the tricyclic antidepressant family. Iproniazid and imipramine made two fundamental contributions to the development of psychiatry: one of a social-health nature, consisting in an authentic change in the psychiatric care of depressive patients; and the other of a purely… CONTINUE READING
    289 Citations
    [The next psychoactive drugs: From imipramine to ketamine].
    A brief history of antidepressant drug development: from tricyclics to beyond ketamine.
    • 24
    • Highly Influenced
    • PDF
    Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
    • 23
    • PDF
    Monoaminergic system and depression
    • 18
    Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
    • 115
    • Highly Influenced
    Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders
    • 94

    References

    SHOWING 1-10 OF 210 REFERENCES
    Pharmacotherapy of depression: a historical analysis
    • T. Ban
    • Psychology, Medicine
    • Journal of Neural Transmission
    • 2001
    • 74
    Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors.
    • 73
    Monoamine Oxidase Inhibitors
    • 154
    Designing new treatments for depression and anxiety.
    • 16
    The Treatment of Depressive Conditions with Imipramine (G 22355) *
    • 58
    The effect of imipramine of central 5‐hydroxytryptamine neurons
    • 198
    CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS.
    • 285